Clinical Trial Update: Safety Study of Nebivolol for COPD Patients [Phase 2, Phase 3]

View source ↗

Summary

A Phase 2/Phase 3 safety study of Nebivolol for chronic obstructive pulmonary disease was withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease
• Hypertension

Drugs mentioned

• Nebivolol (Nebivolol)

Snippet

Sponsor: University of Chicago | Conditions: High Blood Pressure | Phase 2, Phase 3 | Status: WITHDRAWN